PSMB9 and melanoma: This is the first report to establish the association between the overexpression of immunoproteasome subunits PSMB8 and PSMB9 and improved survival and enhanced response to immune-checkpoint inhibitors (both anti-CTLA4 and anti-PD1) in melanoma patients.